Cyclosporine May Alleviate B Symptoms and Induce a Remission of Heavily Pretreated Hodgkin Disease: A Preliminary Report
Authors: MATJAž ZWITTER
Journal: Annals of Internal Medicine (1987)

Brief Reports1 June 1987Cyclosporine May Alleviate B Symptoms and Induce a Remission of Heavily Pretreated Hodgkin Disease: A Preliminary ReportMATJAž ZWITTER, M.D., M.SC., JOžE DRINOVEC, Ph.D., MIRKO DUBRAVČIĆ, M.D., ALENKA VODNIK, M.D., JELKA PETRIČ-GRABNAR, M.D., MAJDA DOLNIČAR, M.D., MIODRAG KONSTANTINOVIĆ, Ph.D., žARKA žEMVA, M.SC.MATJAž ZWITTER, M.D., M.SC.Search for more papers by this author, JOžE DRINOVEC, Ph.D.Search for more papers by this author, MIRKO DUBRAVČIĆ, M.D.Search for more papers by this author, ALENKA VODNIK, M.D.Search for more papers by this author, JELKA PETRIČ-GRABNAR, M.D.Search for more papers by this author, MAJDA DOLNIČAR, M.D.Search for more papers by this author, MIODRAG KONSTANTINOVIĆ, Ph.D.Search for more papers by this author, žARKA žEMVA, M.SC.Search for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-106-6-843 SectionsAboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail ExcerptThe outlook for patients with Hodgkin disease in relapse after receiving several combinations of cytotoxic drugs is still unfavorable. Our preliminary experience with cyclosporine indicates that the introduction of a new drug and a new therapeutic approach deserves further attention in Hodgkin disease, and possibly in other lymphoproliferative disorders.Ten patients with Hodgkin disease who had a biopsy-proven relapse after first- and second-line chemotherapy participated in the study (Table 1). All patients had measurable extranodal disease with B symptoms, normal renal function, and gave informed consent for a new treatment.Cyclosporine was taken orally twice daily, diluted in milk or...References1. ZWITTER M. Hodgkin's disease: five steps from autoimmunity to cancer. Med Hypotheses. 1984;15:399-413. CrossrefMedlineGoogle Scholar2. UYEMURADIXONPARKER KJJ. Cyclosporine inhibits macrophage accessory cell function in mitogen-induced lymphocyte proliferation. Transplant Proc. 1985;17:1374-7. Google Scholar3. WHISLERLINDSEYPROCTORNEWHOUSE RJKY. The impaired ability of human monocytes to stimulate autologous and allogeneic mixed lymphocyte reactions after exposure to cyclosporine: associated alterations of HLA-DR expression and physical characteristics of monocytes. Transplantation. 1985;40:57-61. CrossrefMedlineGoogle Scholar4. FISHERCOSSMANDIEHLVOLKMAN RJVD. Antigen presentation by Hodgkin's disease cells. J Immunol. 1985;135:3568-71. MedlineGoogle Scholar5. HESSCOLOMBANIESA APA. Cyclosporine and the immune response: basic aspects. CRC Crit Rev Immunol. 1986;6:123-49. Google Scholar6. ROSENWASSERBROWNBERNHEIMDINARELLO LTHC. The effects of cyclosporine on different interleukin 1 activities. In: SORG C, SCHIMPL A, LANDY M, eds. Cellular and Molecular Biology of Lymphognes. Orlando, Florida: Academic Press; 1985:823-7. CrossrefGoogle Scholar7. FORDTSAODAVISSAHASRABUDDHEMEHTA RJFCS. Hodgkin's disease in immunologic perspective. In: FORD RJ, FULLER LM, HAGEMEISTER FR, eds. Hodgkin's Diseases and Non-Hodgkin's Lymphoma. New York: Raven Press; 1984;27-34. Google Scholar8. KORTMANNBURRICHTERMONNERJAHNDIEHLPETER CHDGVH. Interleukin-1-like activity constitutively generated by Hodgkin derived cell lines: I. Measurement in a human lymphocyte co-stimulator assay. Immunobiology. 1984;166:318-33. CrossrefMedlineGoogle Scholar9. PALESTINENUSSENBLATTCHAN ARC. Side effects of systemic cyclosporine in patients not undergoing transplantation. Am J Med. 1984;77:652-6. CrossrefMedlineGoogle Scholar This content is PDF only. To continue reading please click on the PDF icon. Author, Article, and Disclosure InformationAffiliations: Institute of Oncology University Clinical Center Ljubljana Military Hospital Clinical Center for Oncology and Radiotherapy Split Yugoslavia PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetails Metrics Cited ByComplications hématologiques malignes, en particulier lymphoprolifératives, après transplantationComplications hématologiques malignes, en particulier lymphoprolifératives, après transplantationDorothy Reed and Hodgkin’s disease: a reflection after a centurySevere pancytopenia and intrahepatic cholestasis in a patient with a history of Hodgkin’s disease.Gingival overgrowth induced by nifedipine and cyclosporin. A Clinical and morphometric study with image analysisEpstein-barr virus-associated Hodgkin's disease following renal transplantationCyclosporine treatment of refractory T-cell lymphomasPrimary Hodgkin's lymphoma: An unusual cause of graft dysfunction after kidney transplantationCyclosporin A (Sandimmun®) in autoimmune disordersAdverse Reactions and Interactions of CyclosporinOn the potential role of cyclosporin in the treatment of lymphoproliferative diseases 1 June 1987Volume 106, Issue 6Page: 843-844KeywordsChemotherapyDrugsHodgkin lymphomaLymphoproliferative disorderMilkRadioimmunoassaysRenal diseasesResearch grants Issue Published: 1 June 1987 PDF DownloadLoading ...